Recent developments in the clinical activity of topoisomerase-1 inhibitors

Update on Cancer Therapeutics

Volumn 1, Issue 2, 2006, Pages 117-145

  Haglof, Karen J ^a   Popa, Elizabeta ^a   Hochster, Howard S ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

9 Amino camptothecin; 9 Nitro camptothecin; Camptothecin(s); Cleavable complex; Edotecarin; Exatecan; Irinotecan; Lurtotecan; Topoisomerase 1; Topoisomerase 1 inhibitor(s); Topotecan

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; 9 AMINOCAMPTOTHECIN; BEVACIZUMAB; BORTEZOMIB; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DE 310; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; EDOTECARIN; ERLOTINIB; ETOPOSIDE; EXATECAN; FLUOROURACIL; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; LURTOTECAN; METHYLPREDNISOLONE; MITOMYCIN C; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OXALIPLATIN; PACLITAXEL; PLATINUM; RADIOSENSITIZING AGENT; RUBITECAN; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CELL DEATH; CLINICAL TRIAL; COLON CANCER; DEHYDRATION; DIARRHEA; DNA REPAIR; DNA REPLICATION; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG METABOLISM; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEVER; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVARY CANCER; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SEPSIS; SKIN DISEASE; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

EID: 33746302266     PISSN: 1872115X     EISSN: 1872115X     Source Type: Journal    
DOI: 10.1016/j.uct.2006.05.010     Document Type: Review

References (265)

1. Hsiang Y.H., Hertzberg R., and Liu L.F. Camptothecin induced protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260 (1985) 14873-14878
2. Hsiang Y.H., and Liu L.F. Identification of mammalian topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 49 (1988) 5077-5082
3. Wang J.C. DNA topisomerases. Ann Rev Biochem 54 (1985) 665-697
4. Herben V.M.M., tenBokkel Huinink W.W., Schellens J.H.M., and Beijnen J.H. Clinical pharmacokinetics of camptothecin topoisomerase I inhibitors. Pharm World Sci 20 4 (1998) 161-172
5. Potmesil M. Camptothecins: from bench research to hospital wards. Cancer Res 54 (1994) 1431-1439
6. Hertzberg R.P., Caranfa M.J., Holden K.G., et al. Modification of hydroxy lactone ring of camptothecain: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 31 (1989) 715-720
7. Adams D.J. The impact of tumor physiology on camptothecin-based drug development. Curr Med Chem Anti-Cancer Agents 5 1 (2005) 1-13
8. Zihou M., and Burke T.G. Marked interspecies variations concerning the interactions of camptothecin with serum albumin: a frequency-domain fluorescence spectroscopic study. Biochemistry 33 (1994) 12445-12450
9. Mi Z., Malak H., and Burke T.G. Reduced albumin binding promotes the stability and activity of topotecan in human blood. Biochemistry 34 (1995) 13722-13728
10. Schrivers D., Higley M.S., de Bruijn E.A., et al. Role of red blood cells in pharmacokinetics of chemotherapeutic agents. Anticancer Drugs 10 (1999) 147-153
11. Loos W., Gelderblom H.J., Verweij J., Brouwer E., de Jonge M.J.A., and Sparreboom A. Gender-dependent pharmacokinetics of topotecan in adult patients. Anticancer Drugs 11 9 (2000) 673-680
12. Xu G., Zhang W., Ma M.K., and McLeod H.L. Human carboxylase-2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin Cancer Res 8 (2002) 2605-2611
13. Guichard S., Terret C., Hennebelle I., et al. CPT-11 converting carboxylesterase and topoisomerase I activities in tumor and normal colon and liver tissues. Br J Cancer 80 (1999) 364-370
14. Sanghani S., Quinney S., Fredenburg T.B., Sun Z., et al. Carboxylesterases expressed in human colon tumor tissue and their role in CPT-11 hydrolysis. Clin Cancer Res 9 (2003) 4983-4991
15. Morishita Y., Fujii M., Kasakura Y., and Takayama T. Effect of carboxylesterase inhibition on the anti-tumour effects of irinotecan. J Int Med Res 33 1 (2005) 84-89
16. Tukey R.H., and Strassburg C.P. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40 (2000) 581-616
17. Massad L., de Waziers I., Ribrag V., et al. Comparison of mouse and human colon tumors with regard to phase I and phase II drug metabolizing enzyme systems. Cancer Res 52 (1992) 6567-6575
18. Tobin, et al. The in vitro metabolism of irinotecan (CPT-11) by carboxylesterase and B-glucuronidase in human colorectal tumours. ASCO-GI Cancer Symp (2005) [abstract 288]
19. Takasuna, et al. Involvement of B-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride. Cancer Res 56 (1996) 3752-3757
20. Liu L.F., Desai S.D., Li T.K., et al. Mechanism of action of camptothecin. Ann NY Acad Sci 922 (2000) 1-10
21. Goldwasser F., Bae I., Valenti M., et al. Topoisomerase I related parameters and camptothecin activity in the colon carcinoma cell lines for the National Cancer Institute anticancer screen. Cancer Res 55 (1996) 2116-2121
22. Wu J., Yin M., Hapke G., Toth K., and Rustum Y.M. Induction of biphasic DNA double strand breaks and activation of multiple repair protein complexes by DNA topoisomerase I drug 7-ethyl-10-hydroxy-camptothecin. Mol Pharmacol 61 (2002) 742-748
23. Pommier Y., Redon C., Rao V.A., Seiler J.A., Sordet O., Takamura H., et al. Repair of and checkpoint response to topoisomerase I-mediated DNA damage. Mutat Res 532 (2003) 173-203
24. Jacob S., Miquel C., Sarasin A., and Praz F. Effects of camptothecin on double-strand break repair by non-homologous end-joining in DNA mismatch repair-deficient human colorectal cancer cell lines. Nucl Acids Res 339 1 (2005) 106-113
25. Villalona-Calero M.A., Kuhn J., Drengler R., Schaaf L., Otterson G.A., Shapiro C., et al. Pharmacologically-based phase I study of mitomycin C (MMC) as a modulator of irinotecan (CPT-11) antitumor activity. Proc Am Soc Clin Oncol (2001) [abstract 400]
26. Kolesar J., Miller J., Duan W., and Villalona-Calero M.A. T1 induction in PMBC by mitomycin-C predicts irinotecan response. Proc Am Soc Clin Oncol (2002) [abstract 456]
27. Hochster H., Liebes L., Speyer J., Sorich J., Taubes B., Oratz R., et al. Effect of prolonged topotecan infusion on topoisomerase I levels: a phase I and pharmacodynamic study. Clin Cancer Res 3 (1997) 1245-1252
28. Aoe K., Kiura K., Ueoka H., Tabata M., Chikamori M., Kohara H., et al. Cisplatin down-regulates topoisomerase I activity in lung cancer cell lines. Anticancer Res 24 6 (2004) 3893-3897
29. Desai S.D., Zhang H., Rodriguez-Bauman A., Yang J.M., Wu X., Gounder M.K., et al. Transcription-dependent degradation of topoisomerase I-DNA covalent complexes. Mol Cell Biol 23 (2003) 2341-2350
30. Cusack J.C., Liu R., Houston M., Abendroth K., Elliot P.J., Adams J., et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappa B inhibition. Cancer Res 61 (2001) 3535-3540
31. 2-terminal kinase activation, fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma. Cancer Res 64 (2004) 8746-8753
32. Thielman H.W., Popanda O., and Staab H.J. Subneuclear distributiona of DNA topoisomerase I and Bax protein in normal and xeroderma pigmentosum fibroblasts after irradiation with UV light and c rays or treatment with topotecan. J Cancer Res Clin Oncol 125 (1996) 193-208
33. Danks M.K., Garrett K.E., Marion R.C., and Whipple D.O. Subcellular distribution of DNA topoisomerase I in anaplastic astrocytoma cells teated with topotecan. Cancer Res 56 (1996) 1664-1673
34. Buckwalter C.A., Lin A.H., Tanizawa A., Pommier Y.G., Cheng Y.C., and Kaufmann S.R. RNA synthesis inhibitors alter the subnuclear distribution of DNA topoisomerase I. Cancer Res 56 (1996) 1674-1681
35. Muller S., Hoege C., Pyrowolakis G., and Jentsch S. SUMO, ubiquitin's mysterious cousin. Nat Rev Mol Cell Biol 2 3 (2001) 202-213
36. Mao Y., Sun M., Desai S.D., and Liu L.F. SUMO-1 conjugation to topoisomerase I: a possible repair response to topoisomerase-mediated DNA damage. PNAS 97 (2000) 4046-4051
37. Mo Y.Y., Yu Y., Shen Z., and Beck W.T. Nucleolar delocalization of human topoisomerase I in response to topotecan correlates with sumoylation of the protein. J Biol Chem 277 4 (2002) 2958-2964
38. Bendetz-Nezer S., Gazit A., and Priel E. DNA topoisomerase I as one of the cellular targets of certain tyrphostin derivatives. Mol Pharmacol 66 3 (2004) 627-634
39. Rowinski E.K., Grochow L.B., Hendricks C.B., Ettinger D.S., et al. Phase I and pharmcologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 10 (1992) 647-665
40. Beran M., O'Brien S., Thomas D.A., Tran H.T., Cortes-Franco J.E., Giles F., et al. Phase I study of oral topotecan in hematological malignancies. Clin Cancer Res 9 (2003) 4084-4091
41. Daw N.C., Santana V.M., Iacono L.C., Furman W.L., Hawkins D.R., Houghton P.J., et al. Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors. J Clin Oncol 22 5 (2004) 829-836
42. Wagner S., Erdlenbruch B., Langler A., Gnekow A., Kuhl J., Albani M., et al. Oral topotecan in children with recurrent or progressive high-grade glioma. Cancer 100 8 (2004) 1750-1757
43. Blaney S.M., Heideman R., Berg S., Adamson P., Gillespie A., Geyer J.R., et al. Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J Clin Oncol 21 1 (2003) 143-147
44. Aisner J., Musanti R., Beers S., Smith S., Locsin S., and Rubin E.H. Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: a pharmacodynamically based phase I trial. Clin Cancer Res 9 (2003) 2504-2509
45. Nemunaitis J., Cunningham C.C., Vukelja S., Ruxer R.L., Adams N., Rich D., et al. Phase I trial of topotecan in combination with gemcitabine in refractory solid tumor patients. Cancer Invest 22 3 (2004) 360-367
46. Kerbusch T., Groenewegen G., Mathot R.A.A., Herben V.M.M., ten Bokkel Huinink W.W., Swart M., et al. Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks. Br J Cancer 90 (2004) 2268-2277
47. Tsao A.S., Shin D.M., Palmer J.L., Lee J.S., and Glisson B.S. Phase I evaluation of docetaxel and topotecan for patients with advanced solid tumors. Cancer 100 10 (2004) 2240-2245
48. Stathopoulos G.P., Rigatos S.K., Christodoulou C., Malamos N.A., Deliyiannis F., Stathopoulos J.G., et al. Weekly administration of topotecan and paclitaxel in pretreated advanced cancer patients: a phase I/II study. Cancer Chemother Pharmacol 54 (2004) 259-264
49. Homesley H., Benigno B., Williams J., and Vaccarello L. A phase I study of weekly topotecan and paclitaxel in previously treated epithelial ovarian carcinoma patients. Gynecol Oncol 87 2 (2002) 171-177
50. Hochster H., Liebes L., Speyer J., Sorich J., et al. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncol 12 (1994) 553-559
51. Hochster H., Wadler S., Runowicz C., Liebes L., et al. Activity and pharmacodynamics of 21-day topotecan infusion in patients with ovarian cancer previously treated with platinum-based therapy. J Clin Oncol 17 8 (1999) 2553-2563
52. Lu J., Hochster H., Sorich, et al. Phase I study of oxaliplatin and topotecan infusion in patients with previously-treated ovarian cancer. Proc Am Soc Clin Oncol 22 (2003) 463 [abstract 1860]
53. Sehouli J., Stengel D., Oskay G., Blohmer J., et al. A new therapeutic approach: topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first line chemotherapy with paclitaxel and platinum. J Obstet Gynecol Res 29 3 (2003) 123-131
54. Penson R.T., Seiden M.V., Goodman A., Fuller A.F., Berkowitz R.S., Matulonis U.A., et al. Phase I trial of escalating doses to topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with mullerian malignancies. Gynecol Oncol 93 (2004) 702-707
55. Dabrow M.B., Francesco M.R., Gilman P.B., Cantor R., Rose L., and Meyer T.J. Combined therapy with topotecan and gemcitabine in patients with inoperable or metastatic non-small cell lung cancer. Cancer Invest 21 4 (2003) 517-525
56. Forouzannia A., Schiller J., Berlin J., Hutson P., Boothman D., Storer B., et al. Lung Cancer 44 (2004) 111-119
57. West W., Birch R., Schnell F., Hainsworth J., et al. Phase I study of paclitaxel and topotecan for the first-line treatment of extensive-stage small cell lung cancer. Oncologist 8 1 (2003) 76-82
58. Lu C., Komaki R., Lee J.S., Shin D.M., Palmer J.L., Coldman B.J., et al. A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer. Clin Cancer Res 9 (2003) 2085-2091
59. Holcombe R.F., Kong K.M., and Wimmer D. Combined topoisomerase I inhibition for the treatment of metastatic colon cancer. Anti-Cancer Drugs 15 6 (2004) 569-574
60. Hutter G., Szelenyi H., Deckert P.M., Keilholz U., and Thiel E. Phase I/II trial of topotecan given as continuous infusion in combination with oxaliplatin in 5-FU-pretreated patients with colorectal cancer. Cancer Chemother Pharmacol 54 (2004) 178-184
61. Coutinho F., Manhani A.R., Velasquez W.S., and del Giglio A. Topotecan, ara-C, cisplatin and prednisolone for patients with refractory and relapsing lymphomas: results of a phase I trial. Acta Haem 112 (2004) 121-125
62. Donato M.L., Aleman A., Champlin R.E., Weber D., Alexanian R., Ippoliti C.M., et al. High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myeloma. Leuk Lymph 45 4 (2004) 755-759
63. Weihrauch M.R., Staib P., Seiberlich B., Hoffman M., Diehl V., and Tesch H. Phase I/II clinical study of topotecan and cytarabine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia. Leuk Lymph 45 4 (2004) 699-704
64. Miller D.S., Blessing J.A., Lentz S.S., and McMeekin D.S. Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group study. Cancer 98 8 (2003) 1664-1669
65. Brown J., Peters W., and Rettenmaier M. Three-consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer. Gynecol Oncol 88 (2003) 136-140
66. Markman M., Webster K., Zanotti K., Kulp B., Peterson G., and Belinson J. Phase 2 trial of prolonged administration of oral topotecan in platinum/taxane-refractory ovarian, fallopian tube, and primary peritoneal cancers. Gynecol Oncol 95 (2004) 109-113
67. Wadler S., Levy D.E., Lincoln S.T., Soori G.S., Schink J.C., and Goldberg G. Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial cancer: eastern cooperative oncology group study E3E93. J Clin Oncol 21 11 (2003) 2110-2114
68. Chambers J.T., Rutherford T.J., Schwartz P.E., Carcangui M.L., Chambes S.K., and Baker L. A pilot study of topotecan in the treatment of serous carcinoma of the uterus. Int J Gynecol Cancer 13 (2003) 216-222
69. Takeda K., Negoro S., Sawa T., Nakagawa K., Kawahara M., et al. A phase II study of topotecan in patients with relapsed small cell lung cancer. Clin Lung Cancer 4 4 (2003) 229-230
70. Belanger K., MacDonald D., Caincross G., Gertler, et al. A phase II study of topotecan in patients with anaplastic oligodendroglioma or anaplastic mixed oligoastrocytoma. Invest New Drugs 21 4 (2003) 473-480
71. Lesimple T., Hassel M.B., Gedouin D., Seigneuret E., et al. Phase I study of topotecan with concurrent radiotherapy in adults with glioblastoma. J Neuroncol 65 2 (2003) 141-148
72. Kramer K., Kushner B., and Cheung N. Oral topotecan for refractoy and relapsed neuroblastoma: a retrospective analysis. J Pediatr Hematol Oncol 25 8 (2003) 601-605
73. Sood A.K., Lush R., Geisler J.P., Shahin M.S., Sanders L., Sullivan D., et al. Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial. Clin Cancer Res 10 (2004) 6080-6085
74. Chiara S., Tognoni A., Pastrone I., Tomasello L., Brema F., DiCostanzo G., et al. Topotecan and ifosfamide as salvage treatment in advanced ovarian cancer. Gynecol Oncol 93 (2004) 474-478
75. Matulonis U., Campas S., Duska L., Fuller A., Berkowitz R., Gore S., et al. A phase II trial of three sequential doublets for the treatment of advanced mullerian malignancies. Gynecol Oncol 91 (2003) 293-298
76. Gordon A.N., Asmar L., Messing M.J., Street D.G., Pippit C.H., Bailey C.L., et al. Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer. Gynecol Oncol 94 (2004) 533-539
77. Tiersten A.D., Selleck M.J., Hershman D.L., Smith D., Resnik E.E., Troxel A.B., et al. Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma. Gynecol Oncol 92 (2004) 635-638
78. Joppert M.G., Garfield D.H., Gregurich M.A., Nemunaitis J.J., Marsland T.A., Khandelwal P., et al. A phase II multicenter study of combined topotecan and gemcitabine as first line chemotherapy for advanced non-small cell lung cancer. Lung Cancer 39 (2003) 215-219
79. Ardizzoni A., Manegold C., Gaafar R., et al. European Organization for Research and Treatment of Cancer (EORTC) 089547 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer. Clin Cancer Res 9 (2003) 143-150
80. Hobdy E.M., Kraut E., Maters G., Blum K., McKeon A., Byrd B., et al. A phase II study of topotecan and cyclophosphamide with G-CSF in patients with untreated, extensive-stage small cell lung carcinoma. Cancer Biol Ther 3 1. (2004)
81. Jett J.R., Hatfield A.K., Hillman S., Bauman M.D., Mailliard J.A., Kugler J.W., et al. Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma. Cancer 97 10 (2003) 2498-2503
82. Felip E., Rosell R., Domine M., Santome L., et al. Sequential dose-dense paclitaxel followed by topotecan in untreated extensive-stage small-cell lung cancer: a Spanish Lung Cancer Group phase II study. Ann Oncol 14 10 (2003) 1549-1554
83. Mavroudis D., Pavlakou G., Blazoyiannakis G., Veslemes M., Apostolopoulou F., Kouroussis C., et al., Greek Cooperative Oncology Group for Lung Cancer. Sequential administration of cisplatin-etoposide followed by topotecan in patients with extensive stage small cell lung cancer, a multicenter phase II study. Lung Cancer 39 (2003) 71-76
84. Bogart J.A., Herndon II J.E., Lyss A.P., Watson D., Miller A.A., Lee M.E., et al. 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B Study 39808. Int J Radiat Oncol 59 2 (2003) 460-468
85. ten Bokel Huinink W., Lane S.R., and Ross G.A. Long-term survival in a phase III randomized study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann Oncol 15 1 (2002) 100-103
86. Gordon A.N., Tonda M., Sun S., Rackoff W., and on behalf of the Doxil Study 30-49 investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 95 (2004) 1-8
87. Carlini, et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res 11 February (3) (2005) 1226-1236
88. Marcuelo, et al. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. BJC 91 August (4) (2004) 678-682
89. Slatter J.G., Scharrf L.J., Sams J.P., et al. Pharmacokinetics, metabolism, and excretion of irinotecan following IV infusion of (14-C) CPT-11 in cancer patients. Drug Metab Dispos 28 (2000) 423-433
90. Tamura, et al. Prevention of irinotecan-induced diarrhea by oral sodium bicarbonate and influence on pharmacokinetics. Oncology 67 (2004) 327-337
91. Brittain, et al. Phase II study of activated charcoal to prevent irinotecan-induced diarrhea. J Clin Oncol 22 November (21) (2004) 4410-4417
92. Inocenti, et al. A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital. Clin Pharmacol Ther 76 November (5) (2004) 490-502
93. Takeda, et al. Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients. Int J Cancer 92 April (2) (2001) 269-275
94. Rougier, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352 October (9138) (1998) 1407-1412
95. Van Cutsem E., Cunningham D., Bokkel Huinink W.W., Punt C.J., Alexopoulos C.G., Dirix L., et al. Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU). Eur J Cancer 35 1 (1999) 54
96. Saltz, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343 September (13) (2000) 905-914
97. Douillard, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 355 March (9209) (2000) 1041-1047
98. Soepenberg, et al. Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors. Clin Cancer Res 11 February (4) (2005) 1504-1511
99. Soepenberg, et al. Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors. J Clin Oncol 23 February (4) (2005) 889-898
100. Pal, et al. Preclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulation. Anticancer Res 25 January-February (1A) (2005) 331-341
101. http://www.cancer.gov/clinicaltrials/NCCTG-N0147
102. Wasserman E., Cuvier C., Lokiec F., et al. Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics. J Clin Oncol 17 (1999) 1751-1759
103. Goldberg R.M., Sargent D.J., Morton R.F., Fuchs C.S., Ramanathan R.K., Williamson S.K., et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22 January 1 (2004) 23-30
104. deGramont, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. JCO August (2000) 2938-2947
105. Andre, et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR Eur J Cancer 35 September (9) (1999) 1343-1347
106. Tournigand, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22 January 2 (2004) 229-237
107. Maughan et al. Fluorouracil (FU), oxaliplatin (OX), CPT-11 (irinotecan, Ir), use and sequencing, in advanced colorectal cancer (ACRC): The UK MRC FOCUS (CR08) Trial ASCO 2005 Gastrointestinal Cancers Symposium.
108. Mitry et al. Comparison of the tolerance and efficacy of LV5FU2-CPT11 and FOLFIRI regimens in front-line treatment of advanced colorectal cancer-A pooled analysis of 254 patients included in 2 randomised trials ASCO 2005 Gastrointestinal Cancers Symposium Abstract # 3579.
109. Mitry, et al. Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials. Ann Oncol 15 July (7) (2004) 1013-1017
110. Lal, et al. A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidin and thymidylate synthase inhibitor-resistant advanced colorectal cancer. JCO August (2004) 3023-3031
111. Schoemaker, et al. A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer. Br J Cancer 91 October (8) (2004) 1434-1441
112. Masi, et al. A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed. Clin Cancer Res 10 March (5) (2004) 1657-1663
113. Mabro M., Artru P., Flesch M., Maindrault-Goebel F., André T., Lledo G., et al. Irinotecan, 5-fluorouracil infusion and leucovorin (FOLFIRI-3) in pretreated patients with metastatic colorectal cancer: results of a multicenter phase II study. Proc Am Soc Clin Oncol 22 (2003) 280 [abstract 1125]
114. Bajetta, et al. Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer 100 January (2) (2004) 279-287
115. Saltz, et al. Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803. ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clinical Oncol 22 July Suppl. (14S) (2004) 3500
116. VanCutsem E., Labianca R., Hossfeld D., et al. Randomized phase III trial comparing infused irinotecan/5-fluoruracil and folinic acid (IF) versus FU/FA (F) in stage III colon cancer patients (PETACC-3, v307). Proc American Soc Clin Oncol (2005) [Abstract 18]
117. Hurwitz, et al. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. N Engl J Med 350 June (2004) 2335-2342
118. Cunningham, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 July (2004) 337-345
119. Messersmith, et al. Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities. Clin Cancer Res 10 October (19) (2004) 6522-6527
120. Redlinger, et al. A phase II trial of gefitinib in combination with 5-FU/LV/irinotecan in patients with colorectal cancer. ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clinical Oncol 22 July Suppl. (14S) (2004) 3767
121. http://cancer.gov/clinicaltrials/NCCTG-N0147
122. Taieb, et al. Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study. J Clin Oncol 23 January 3 (2005) 502-509
123. National Institutes of Health Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. J Am Med Assoc 264 (1990) 1444-1450
124. Klautke, et al. Intensified concurrent chemoradiotherapy with 5-fluorouracil and irinotecan as neoadjuvant treatment in patients with locally advanced rectal cancer. Br J Cancer March (2005)
125. Hofheinz, et al. Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer. J Clin Oncol 23 (2005) 1350-1357
126. Futatsuki K., Wakui A., Nakao I., et al. Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group. Gan To Kagaku Ryoho 21 (1994) 1033-1038
127. Kohne C.H., Catane R., Klein B., et al. Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial. Br J Cancer 89 (2003) 997-1001
128. Ohtsu A., Shimada Y., Shirao K., et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 21 1 (2003) 54-59
129. Pozzo, et al. Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. Ann Oncol 15 December (12) (2004) 1773-1781
130. Bouche, et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study-FFCD 9803. J Clin Oncol 22 November (21) (2004) 4319-4328
131. Assersohn, et al. Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol 15 January (1) (2004) 64-69
132. Ajani, et al. Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Cancer 100 June (11) (2004) 2347-2354
133. Shah et al. Multicenter phase II study of irinotecan (CPT), cisplatin (CIS), and bevacizumab (BEV) in patients with unresectable or metastatic gastric or gastroesophageal (GEJ) adenocarcinoma. ASCO 2005 Gastrointestinal Cancers Symposium.
134. Conroy, et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer-A Groupe Tumeurs Digestives of the Fédération Nationale des Centres de Lutte Contre le Cancer Study. JCO Feburary (2005) 1228-1236
135. Rocha Lima, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. JCO September (2004) 3776-3783
136. Baker et al. Phase II study of irinotecan (CPT-11) in advanced non-small cell lung cancer (NSCLC) ASCO 1997 Annual Meeting abstract #1658.
137. Negoro, et al. Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br J Cancer 88 (2003) 335
138. Fukuda, et al. Phase II study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer. Cancer Chemother Pharmacol 54 December (6) (2004) 573-577 [Epub 2004 Sep 10]
139. Pectasides, et al. Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial. Ann Oncol 16 Feburay (2) (2005) 294-299
140. Wachters, et al. A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment. Br J Cancer 92 January (1) (2005) 15-20
141. Raez, et al. Irinotecan and docetaxel as first-line chemotherapy in patients with stage IIIB/IV non-small cell lung cancer. ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clinical Oncol 22 July Suppl. (14S) (2004) 7246
142. Vasillis, et al. Second-line treatment with Irinotecan (CPT-11) and cisplatin (CDDP) versus CDDP alone in patients with advanced NSCLC pretreated with taxanes and gemcitabine: final results of a multicenter randomized phase II study. Proc Am Soc Clin Oncol 22 (2003) 626 [abstract 2516]
143. Yamamoto, et al. Randomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803). Br J Cancer 90 January (1) (2004) 87-92
144. Rocha Lima, et al. Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC. Ann Oncol 15 March (3) (2004) 410-418
145. Miller, et al. Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced non-small cell lung cancer (NSCLC). ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clinical Oncol 22 July Suppl. (14S) (2004) 7132
146. Noda, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346 January (2) (2002) 85-91
147. Goto, et al. Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer. Br J Cancer 91 August (4) (2004) 659-665
148. Ando, et al. Weekly administration of irinotecan (CPT-11) plus cisplatin for refractory or relapsed small cell lung cancer. Lung Cancer 44 April (1) (2004) 121-127
149. Wu, et al. Irinotecan in combination with radiation therapy for small-cell and non-small-cell lung cancer. Oncology (Huntingt) 16 September (9 Suppl. 9) (2002) 13-18
150. Socinski, et al. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial. J Clin Oncol 22 November (21) (2004) 4341-4350
151. Tothy, et al. A phase I study of induction chemotherapy (CT) and concomitant chemoradiotherapy (CRT) with carboplatin (C), paclitaxel (P), and irinotecan (I) for stage III non-small cell lung cancer (NSCLC). ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clinical Oncol 22 July Suppl. (14S) (2004) 7170
152. Shigeoka, et al. Clinical effect of irinotecan in advanced and metastatic breast cancer patients previously treated with doxorubicin- and docetaxel-containing regimens. Jpn J Clin Oncol 31 August (8) (2001) 370-374
153. Perez, et al. Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol 22 July (14) (2004) 2849-2855
154. Turner C.D., Gururangan S., Eastwood J., et al. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. Neuro-Oncol 4 (2002) 102-108
155. Friedman H.S., Petros W.P., Friedman A.H., et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 17 (1999) 1516-1525
156. Batchelor, et al. Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. Neuro-Oncol 6 January (1) (2004) 21-27
157. Reardon, et al. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer 103 January (2) (2005) 329-338
158. Gilbert M.R., Supko J.G., Batchelor T., et al. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res 9 (2003) 2940-2949
159. Brandes, et al. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol 22 December (23) (2004) 4779-4786 [Erratum in: J Clin Oncol 2005 1;(Januray 23):248]
160. Gruber M.L., and Buster W.P. Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma. Am J Clin Oncol 27 (2004) 33-38
161. Kushner B.H., Kramer K., Modak S., and Cheung N.K. Five-day courses of irinotecan as palliative therapy for patients with neuroblastoma. Cancer 103 February (4) (2005) 858-862
162. Kushner B.H., Kramer K., Modak S., and Cheung N.-K.V. Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma. Clin Cancer Res 10 (2004) 84-87
163. Look K.Y., Blessing J.A., Levenback C., Kohler M., Chafe W., and Roman L.D. A phase II trial of CPT-11 in recurrent squamous carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 70 (1998) 334-338
164. Umesaki, et al. Phase II study of irinotecan combined with mitomycin-C for advanced or recurrent squamous cell carcinoma of the uterine cervix: the JGOG study. Gynecol Oncol 95 October (1) (2004) 127-132
165. Aoki, et al. Combination chemotherapy with irinotecan hydrochloride (CPT-11) and mitomycin C in platinum-refractory ovarian cancer. Am J Clin Oncol 27 October (5) (2004) 461-464
166. Markman M., Hall J., Spitz D., et al. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol 20 (2002) 2365-2369
167. Escobar, et al. Phase 2 trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers. Gynecol Oncol 92 January (1) (2004) 192-196
168. Suzumiya, et al. Phase I study of the combination of irinotecan hydrochloride, carboplatin, and dexamethasone for the treatment of relapsed or refractory malignant lymphoma. Int J Hematol 79 April (3) (2004) 266-270
169. Ribrag, et al. Phase II trial of irinotecan (CPT-11) in relapsed or refractory non-Hodgkin's lymphomas. Leuk Lymphoma 44 September (9) (2003) 1529-1533
170. Wagner L.M., Crews K.R., Iacono L.C., Houghton P.J., Fuller C.E., McCarville M.B., et al. Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res 10 February (3) (2004) 840-848
171. Bomgaars, et al. A phase I study of irinotecan administered on a weekly schedule in pediatric patients. Pediatr Blood Cancer March (2005)
172. Crews, et al. Effect of fractionated ifosfamide on the pharmacokinetics of irinotecan in pediatric patients with osteosarcoma. J Pediatr Hematol Oncol 26 November (11) (2004) 764-767
173. Wani M.C., Nicholas A.W., and Wall M.E. Plant antitumor agents. 23. Synthesis and antileukemic activity of campothecin analogues. J Med Chem 29 (1986) 2358-2363
174. Giovanella B.C., Stehlin J.S., Wall M.E., Wani M.C., Nicholas A.W., Liu L.F., et al. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246 (1989) 1046-1048
175. Potmesil M., Arbuck S.G., Takimoto C.H., Liebes L., and Hochster H. 9-Aminocamptothecin and beyond. Preclinical and clinical studies. Ann NY Acad Sci 803 (1996) 231-246
176. Potmesil M. Camptothecins: from bench research to hospital wards. Cancer Res 54 (1994) 1431-1439
177. Takimoto C.H. Why drugs fail: of mice and men revisited. Clin Cancer Res 7 (2001) 229-230
178. Hochster H., Liebes L., Speyer J., Sorich J., Chachoua A., Raphael B., et al. Phase I and pharmacodynamic study of prolonged infusion 9-amino-camptothecin (9-AC) in two formulations. Proc Am Soc Clin Oncol (1997) [abstract #704]
179. Rubin E., Wood V., Bharti A., Trites D., Lynch C., Hurwitz S., et al. A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. Clin Cancer Res 1 (1995) 269-276
180. Eder J.P., Supko J.G., Lynch T., Bryant M., Vosburgh E., Shulman L.N., et al. Phase I trial of colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-h continuous infusion. Clin Cancer Res 4 (1998) 317-324
181. Leguizamo J., Quinn M., Takimoto C.H., Liang M.D., Ismail A.-S.A., Pang J., et al. A phase I study of 9-aminocamptothecin as a colloidal dispersion formulation given as a fortnightly 72-h infusion. Cancer Chemother Pharmacol 52 (2003) 333-338
182. Xiong H.Q., Tran H.T., Madden T.L., Newman R.A., and Abbruzzese J.L. Phase I and pharmacological study of oral 9-aminocamptothecin colloidal dispersion (NSC 603071) in patients with advanced solid tumors. Clin Cancer Res 9 (2003) 2066-2071
183. Mani S., Iyer L., Janisch L., Wang X., Fleming G.F., Schilsky R.L., et al. Phase I and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071). Cancer Chemother Pharmacol 42 (1998) 84-87
184. Pitot H.C., Knost J.A., Mahoney M.R., Kugler J., Krook J.E., Hatfield A.K., et al. A north central cancer treatment group phase II trial of 9-aminocamptothecin in previously untreated patients with measurable metastatic colorectal carcinoma. Cancer 89 8 (2000) 1699-1705
185. Pazdur R., Medgysey D.C., Winn R.J., Dakhil S.R., Moore D.F., Scalzo A., et al. Phase II trail of 9-aminocamptothecin administered as a 120-h continuous infusion weekly for three weeks in metastatic colorectal carcinoma. Invest New Drugs 16 (1999) 341-346
186. Saltz L.B., Kemeny N.E., Tong W., Harrison J., Berkery R., and Kelsen D.P. 9-Aminocamptothecin by 72-h continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma. Cancer 80 9 (2000) 1727-1732
187. Pazdur R., Diaz-Canton E., Ballard W.P., Bradof J.E., Graham S., Arbuck S.G., et al. Phase II trial of 9-aminocamptothecin administered as a 72-h continuous infusion in metastatic colorectal carcinoma. J Clin Oncol 15 (1997) 2905-2909
188. Kindler H.L., Avadhani A., Wade-Oliver K., Karrison T., Mani S., and Vokes E.E. 9-Aminocamptothecin (9-AC) given as a 120-h continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium. Invest New Drugs 22 (2004) 323-327
189. Volkes E.E., Ansari R.H., Masters G.A., Hoffman P.C., Klepsch A., Ratain M.J., et al. A phase II study of 9-aminocamptothecin in advanced non-small cell lung cancer. Ann Oncol 10 (1998) 1085-1090
190. Volkes E.E., Gordon G.S., Rudin C.M., Mauer A.M., Watson S., Krauss S., et al. A phase II trial of 9-aminocamptothecin as a 120-h infusion in patients with non-small cell lung cancer. Invest New Drugs 19 (2001) 329-333
191. Hochberg F., Grossman S.A., Mikkelsen T., Glantz M., et al. Lack of efficacy of 9-aminocamptothecin in patients with newly diagnosed glioblastoma multiforma and recurrent high-grade astrocytoma. Neuro-Oncol 2 (2002) 29-33
192. Lad T., Rosen F., Sciortino D., Brackstein B., Keubler J.P., Arreita R., et al. Phase II trial of 9-aminocamptothecin in patients with advanced squamous cell head and neck cancer. Invest New Drugs 18 (2000) 261-263
193. Hochster H., Plimack E.R., Runowicz C.D., Speyer J., Wallach R.C., Sorich J., et al. Biweekly 72-h 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group. J Clin Oncol 22 1 (2004) 120-126
194. Miller D.S., Blessing J.A., Waggoner S., Schilder J., Sorosky J., Bloss J., et al. Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resisitant ovarian and primary peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 96 (2005) 67-71
195. Pantazis P., Harris N., Mendoza J., and Giovanella B. Conversion of 9-nitro-camptothecin to 9-amino-camptothecin by human blood cells in vitro. Eur J Haematol 53 (1994) 246-248
196. Pantazis P., Harris N., Mendoza J., and Giovanella B. The role of pH and serum albumin in the metabolic conversion of 9-nitrocamptothecin to 9-aminocamptothecin by human hematopoetic and other cells. Eur J Haematol 55 (1995) 211-213
197. Chow D., Gong L., Wolfe M.D., and Giovanella B.C. Modified lactone/carboxylate salt equilibria in vivo by liposomal delivery of 9-nitrocamptothecin. Ann NY Acad Sci 922 (2000) 164-174
198. Giovanella B.C., Stelhin J.S., Hinz H.R., Kozieski A.J., et al. Preclinical evaluation of the anticancer activity and toxicity of 9-nitro-20(S)-camptothecin (rubitecan). Int J Oncol 20 (2002) 81-88
199. Verschraegen C.F., Natelson E.A., Giovanella B.C., Kavanaugh J.J., Kudelka A.P., Freedman R.S., et al. A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor. Anticancer Drugs 9 (1998) 36-44
200. Michaelson M.D., Ryan D.P., Fuchs C.S., Supko J.G., Garcia-Carbonero R., Eder J.P., et al. A phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors. Cancer 97 1 (2003) 148-154
201. Calvo E., Rownisky E.K., Tolcher A.W., Chu Q.S., Beeram M., Forero L., et al. A phase I and pharmacokinetic study of rubitecan, an orally administered topoisomerase I (topo-I) inhibitor, combined with gemcitabine in patients with advanced cancer. Proc Am Soc Clin Oncol 22 (2004) 14S [abstract 2099]
202. Koshina N.V., Kleinerman E.S., Waidrep C., Jia S.F., Worth L.L., Gilbert B.E., et al. 9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice. Clin Cancer Res 6 (2000) 2876-2880
203. Verschraegen C.F., Gilbert B.E., Huaringa A.J., Newman R., Harris N., Leyva F.J., et al. Feasibility, phase I, and pharmacological study of aerosolized liposomal 9-nitro-20(S)-camptothecin in patients with advanced malignancies in the lungs. Ann NY Acad Sci 922 (2000) 352-354
204. Verschraegen C.F., Gilbert B.E., Loyer E., Huaringa A., Walsh G., Newman R.A., et al. Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(S)-camptothecin in patients with advanced pulmonary malignancies. Clin Cancer Res 10 (2004) 2319-2326
205. Lawson K.A., Anderson K., Snyder R.M., Simmons-Menchaca M., Atkinson J., Sun L.Z., et al. Novel vitamin E analogue and 9-nitro-camptothecin administered as liposome aerosols decrease syngeneic mouse mammary tumor burden and inhibit metstasis. Cancer Chemother Pharmacol 54 5 (2004) 421-431
206. Zamboni W.C., Jung L.L., Egorin M.J., Potter D.M., Friedland D.M., Belani C.P., et al. Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors. Clin Cancer Res 10 (2004) 5058-5064
207. Jung L.L., Ramanathan R.K., Egorin M.J., Jin R., Belani C., Potter D.M., et al. Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors. Cancer Chemother Pharmacol 54 (2004) 487-496
208. Stehlin J.S., Giovanella B.C., Natelson E.A., De Ipolyi P.D., Coil D., Davis B., et al. A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer. Int J Oncol 14 (1999) 821-831
209. Verschraegen C.F., Gupta E., Loyer E., Kavanaugh J.J., Kudelka A.P., Freedman R.S., et al. A phase II study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer. Anticancer Drugs 1 (1999) 375-383
210. Patel S.R., Beach J., Papdopoulos N., Burgess M.A., Trent J., Jenkins J., et al. Results of a 2-arm phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas. Cancer 97 11 (2003) 2848-2852
211. de Jong M.J.A., Droz J.P., Paz-Ares L., van Oosterom A.T., de Wit R., Chollet P., et al., for the EORTC-New Drug Development Group/New Drug Development Program. Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors. Invest New Drugs 17 47 (2004) 329-333
212. Amin A., Halabi S., Gelmann E.P., Stadler W., Vogelzang N., and Small E. 9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: results of the CALGB 99901. Urol Oncol 22 (2004) 398-403
213. Miller K.D., Soule S.E., Haney L.T.G., Guiney P., Murry D.J., Lenaz L., et al. A Phase II study of 9-nitro-camptothecin in patients with previously treated metastatic breast cancer. Invest New Drugs 22 (2004) 69-73
214. Punt C.J.A., de Jonge M.J.A., Monfardini S., Daugaard G., Fiedler W., Baron B., et al. RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group. Eur J Cancer 40 (2004) 1332-1334
215. Burris H.A., Rivkin S., Reynolds R., Harris J., Wax A., Gerstein H., et al. Phase II trial of oral rubitecan in previously treated pancreatic cancer patients. Oncology 10 (2005) 183-190
216. Jacobs A.D., Burris H.A., Rivkin S., Ritch P.S., Eisenberg P.D., and Mettinger K.L. A randomized phase III study of rubitecan (ORA) vs. best choice (BC) in 409 patients with refractory pancreatic cancer report from a North-American multi-center study. Proc Am Soc Clin Oncol (2004) [abstract 4013]
217. Emerson D.L., Besterman J.M., Brown H.R., Evans M.G., Leitner P.P., Luzzio M.J., et al. In vivo antitumor activity of two new seven-sustituted water-soluble camptothecin analogues. Cancer Res 55 3 (1995) 603-609
218. Gerrits C.J.H., Creemers G.J., Schellens J.H.M., Wissel P., Planting ASTh, Kunka R., et al. Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily × 5 intravenous administration. Br J Cancer 73 (1996) 744-750
219. Eckhardt S.G., Baker S.D., Eckhardt J.R., Burke T.G., Warner D.L., Kuhn J.G., et al. Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks. Clin Cancer Res 4 (1998) 595-604
220. Paz-Ares L., Kunka R., DeMaria D., Cassidy J., Alden M., Beranek P., et al. A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion. B J Cancer 78 10 (1998) 1329-1336
221. Stevenson J.P., DeMaria D., Sludden J., Kaye S.B., Paz-Ares L., Grochow L.B., et al. Phase I/pharmacokinetic study of the topoisomeraser I inhibitor GG211 administered as a 21-day continuous infusion. Ann Oncol 10 3 (1999) 339-344
222. Sessa C., Wanders J., Roelvink M., Dombernowsky P., Nielsen D., Morant R., et al. Second-line treatment of small-cell lung cancer with the camptothecin-derivative GI147211: a study of the EORTC Early Clinical Studies Group (ECSG). Ann Oncol 11 2 (2000) 207-210
223. Gamucci T., Paridaens R., Heinrich B., Schellens J.H., Pavlidis N., Verweij J., et al. Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: an EORTC-ECSG phase II clinical study. Ann Oncol 11 2 (2000) 793-797
224. Gerrits C.J.H., Schellens J.H.M., Creemers G.J., Wissel P., Planting A.S.T.h., Pritchard J.F., et al. The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor. B J Cancer 76 7 (1997) 946-951
225. Emerson D.L., Bendele R., Brown E., Chiang S., Desjardins J.P., Dihel L.C., et al. Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance lipsomal formulation of lurtotecan. Clin Cancer Res 6 (2000) 2903-2912
226. Eisenhauer E.A., Verweij J., Rothenberg M.L., Demetri G., DeVries E.E.G., Gelmon K.A., et al. Phase I evaluation of liposomal topoisomerase I inhibitor, NX211, administeredby three schedules to patients with advanced solid tumors. Proc Am Soc Clin Oncol 21 (2001) [Abstract 409]
227. Gelmon K., Hirte H., Fisher B., Walsh W., Ptaszynski M., Hamilton M., et al. A phase I study of OSI-211 given as an intravenous infusion days 1, 2 and 3 every three weeks in patients with solid cancers. Invest New Drugs 22 3 (2004) 263-275
228. MacKenzie M.J., Hirte H.W., Siu L.L., Gelmon K., Ptaszynski M., Fisher B., et al. A phase I study of OSI-211 and cisplatin as intravenous infusions given on days 1, 2 and 3 every three weeks in patients with solid cancers. Ann Oncol 15 4 (2004) 665-670
229. Giles F.J., Tallman M.S., Garcia-Manero G., Cortes J.E., Thomas D.A., Wierda W.G., et al. Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia. Cancer 100 7 (2004) 1449-1458
230. Seiden M.V., Muggia F., Astrow A., Matulonis U., Campos S., Roche M., et al. A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer. Gynecol Oncol 93 1 (2004) 229-232
231. Duffaud F., Borner M., Chollet P., Vermorken J.B., Bloch J., Degardin M., et al., for the EORTC-New Drug Development Group/New Drug Development Program. Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cellcarcinoma of the head and neck. An EORTC New Drug Development Group Study. Eur J Cancer 40 (2004) 2748-2752
232. Dark G.G., Calvert H., Grimshaw R., Poole C., Swenerton K., Kaye S., et al. Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the National Cancer Institute of Canade Clinical Trials Group. J Clin Oncol 23 9 (2005) 1859-1866
233. Mitsui I., Kumazawa E., Hirota Y., Aonuma M., Sugimori M., Ohsuki S., et al. A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo. Jpn J Cancer Res 86 (1995) 776-782
234. Takiguchi S., Kumazawa E., Shimazoe T., Tohgo A., and Kono A. Antitumor effect of DX-8951, a noval camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice. Jpn J Cancer Res 88 (1997) 760-769
235. Kumazawa E., Jimbo T., Ochi Y., and Tohgo A. Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice. Cancer Chemother Pharmacol 42 (1998) 210-220
236. Rowinsky E.K., Johnson T.R., Geyer Jr. C.E., Hammond L.A., Eckhardt S.G., Drengler R., et al. DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies. J Clin Oncol 18 17 (2000) 3151-3163
237. Boige V., Raymond E., Faivre S., Gatineau M., Meely K., Mekhaldi S., et al. Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-min infusion every 3 weeks in patients with advanced cancer. J Clin Oncol 18 23 (2000) 3986-3992
238. Royce M.E., Hoff P.M., Dumas P., Lassere Y., Lee J.J., Coyle J., et al. Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog. J Clin Oncol 19 5 (2001) 1493-1500
239. Sharma S., Kemeny N., Schwartz G.K., Kelsen D., O'Reilly E., Ilson D., et al. Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-h infusions three of every four weeks. Clin Cancer Res 7 (2001) 3963-3970
240. Giles F.J., Cortes J.E., Thomas D.A., Garcia-Manero G., Faderl S., Jeha S., et al. Phase I and pharmacokinetc study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia. Clin Cancer Res 8 (2002) 2134-2141
241. Braybrooke J.P., Boven E., Bates N.P., Ruijter R., Dobbs N., Cheverton P.D., et al. Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecn mesylate (DX-8951f), using a weekly 30-min intravenous infusion, in patients with advanced solid malignancies. Ann Oncol 14 (2003) 913-921
242. Garrison M.A., Hammond L.A., Geyer Jr. C.E., Schwartz G., Tolcher A.W., Smetzer L., et al. A phase I and pharmacokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies. Clin Cancer Res 9 (2003) 2527-2537
243. Braybrooke J.P., Ranson M., Manegold C., Mattson K., Thatcher N., Cheverton P., et al. Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancer. Lung Cancer 41 (2003) 215-219
244. Esteva F.J., Rivera E., Cristofanilli M., Valero V., Royce M., Duggal A., et al. A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast cancer. Cancer 98 5 (2003) 900-907
245. Verschaegen C.F., Kudelka A.P., Hu W., Vincent M., Kavanaugh J.J., Loyer E., et al. A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan. Cancer Chemother Pharmacol 53 (2004) 1-7
246. Royce M.E., Rowinsky E.K., Hoff P.M., Coyle J., De Jager R., Pazdur R., et al. A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for five days every three weeks to patients with metastatic adenocarcinoma of the colon or rectum. Invest New Drugs 22 (2004) 53-61
247. Clamp A., Adams M., Atkinson R., Boven E., Calvert A.H., Cervantes A., et al. A phase IIA study of the topoisomerase inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer. Gynecol Oncol 95 (2004) 114-119
248. O'Reilly E.M., Hoff P.M., Mani S., Schwartz G., Aird S., Sharma S., et al. A phase I study of DX-8951f (exatecan mesylate, DX) and gemcitabine (Gem) in advanced solid tumors. Proc Am Soc Clin Oncol (2001) [abstract 412]
249. D'Adamo D., Hammond L., Donehower R., Sharma S., Aird S., Kelsen D.P., et al. Final results of a phase II study of DX-8951f (exatecan mesylate, DX) in advanced pancreatic cancer. Proc Am Soc Clin Oncol (2001) [abstract 532]
250. Cheverton P., Friess H., Andras C., Salek T., Geddes C., Bodoky G., et al. Phase III results of exatecan (DX-8951f) versus gemcitabine (Gem) in chemotherapy-naïve patients with advanced pancreatic cancer (APC). Proc Am Soc Clin Oncol (2004) [abstract 4005]
251. O'Reilly E.M., Abou-Alfa G.K., Letourneau R., Harker W.G., Modiano M., Hurwitz H., et al. A randomized phase III trial of DX-8951f (exatecan mesylate; DX) and gemcitabine (GEM) vs. gemcitabine alone in advanced pancreatic cancer (APC). Proc Am Soc Clin Oncol (2004) [abstract 4006]
252. Maeda H. The enhanced permeability and retention (EPR) effecting tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 41 (2001) 189-207
253. Kumazawa E., and Ochi Y. DE-310, a novel macromolecular carrier system for the camptothecin analog DX-8951f: potent antitumor activities in various murine tumor models. Cancer Sci 95 2 (2004) 168-175
254. Masubuchi N. Pharmacokinetics of DE-310, a novel macromolecular carrier system for the camptothecin analog DX-8951f, in tumor-bearing mice. Pharmazie 59 5 (2004) 374-377
255. Ochi Y., Shiose Y., and Kumazawa E. A possible mechanism for the long-lasting antitumor effect of the macromolecular conjugate DE-310: mediation by cellular uptake and drug release of its active camptothecin analog DX-8951. Cancer Chemother Pharmacol 55 4 (2005) 323-332
256. Soepenberg O., de Jonge M.J.A., Sparreboom A., de Bruin P., Eskens F.A.L.M., de Heus G., et al. Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors. Clin Cancer Res 11 (2005) 703-711
257. Lewis L., Perez R., Petros W., Matsumoto M., Natsumeda Y., and Rothenberg M. A phase-1 study of the novel topoisomerase-I inhibitor J-107088 administered on a multiple-dose schedule. Proc Am Soc Clin Oncol (2000) [abstract 688]
258. Peck R. Phase I trial of J-107088, a novel topoisomerase I inhibitor, administered once every 21 days. Proc Am Soc Clin Oncol (2000) [abstract 767]
259. Yamada Y., Yamamoto N., Shimoyama T., Ueda Y., Murakami H., Kusaba H., et al. Phase I trial of J-107088, a novel topoisomerase I inhibitor, administered once every 21 days. Proc Am Soc Clin Oncol (2002) [abstract 385]
260. Perez R.P., Hurwitz H., Nahum K., Lee J., Shiba D., Garcia M., et al. Phase II trials of J-107088, a non-camptothecin topoisomerase I inhibitor, in irinotecan naïve/refractory metastatic colorectal cancer. Proc Am Soc Clin Oncol (2002) [abstract 632]
261. www.jei.org/Archive/BR99/359x/359_JinUS_chem.html
262. www.biospace.com/news_story.cfm?storyID=10403620&full=1
263. Nahum K., Shiba D., Padavanija P., Garcia M., Hurwitz H., Mackintosh F., et al. Phase II efficacy and tolerability study of edotecarin (J-107088) in patients with irinotecan-naïve metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 22 (2003) 274 [abstract 1099]
264. www.inpharm.com/External/InpH/12580,1-4-0-0-inp_intelligence_news-0-33909900.html
265. www.pfizer.com/are/investors_releases/2005pr/mn_2005_0405.cfm